Author(s):
Kapil Sharma, Parven Ranga, Maha Singh, Rajeev Kumar, Haroon Khan, Vikram Tanwar
Email(s):
dr.parveenranga@gmail.com
DOI:
10.52711/0974-360X.2023.00033
Address:
Kapil Sharma1, Parven Ranga2*, Maha Singh3, Rajeev Kumar4, Haroon Khan5, Vikram Tanwar6
1Assistant Professor, Tuberculosis and Respiratory Diseases SHKMGMC.
2Senior resident Deptt., Dentistry SHKMGMC.
3Professor Deptt., Pediatrics SHKMGMC.
4Associate Professor, Community Medicine SHKMGMC.
5Assistant Professor Deptt., of Medicine SHKMGMC.
6Professor Deptt., of Forensic Medicine SHKMGMC.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2023
ABSTRACT:
Background: We assess the profile of adverse events following immunization of COVID – 19 vaccination of COVISHIELD in health care workers (HCWs) in Shaheed Hasan Khan Mewati Govt. Medical college Nalhar, Nuh, Haryana, India. Methods: The Cross sectional and prospective observational study was conducted with a period of 3 months or till the desired sample size recruited in the study with follow up period of 15 days for all those subjects who were vaccinated for covid-19 in SHKM, GMC Hospital to look for AEFI with sample size more than 300. Active surveillance was done on days 3, 6 and 9 after days of vaccination for AEFI). Any AEFI noted will be managed as per the standard guidelines. Results: We present the results of an interim analysis of 400 patients out of total 550 participants with 244(61.00%) male and 156 (39.00%) female participants respectively. AEFIs following ?rst dose were reported in 400 participants and 269 participants after second dose. Fever was the major AEFI with 150(37.50%) after first dose and 78(28.99%) after second dose respectively. In the study age wise AEFIs percentage of participants were also calculated. In the present study different systemic diseases percentage also calculated. Conclusion: The AEFIs associated with the COVISHIELD (ChAdOx1 nCoV-19), the COVID-19 vaccine injected in hospital health care workers is found to be safe for use in except for a few minor reactions.
Cite this article:
Kapil Sharma, Parven Ranga, Maha Singh, Rajeev Kumar, Haroon Khan, Vikram Tanwar. Assessment of Adverse events following Immunization of COVID – 19 vaccination in Health Care Workers (HCWs) of Shaheed Hasan Khan Mewati Govt. Medical College Nalhar, Nuh, Haryana, India. Research Journal of Pharmacy and Technology 2023; 16(1):179-3. doi: 10.52711/0974-360X.2023.00033
Cite(Electronic):
Kapil Sharma, Parven Ranga, Maha Singh, Rajeev Kumar, Haroon Khan, Vikram Tanwar. Assessment of Adverse events following Immunization of COVID – 19 vaccination in Health Care Workers (HCWs) of Shaheed Hasan Khan Mewati Govt. Medical College Nalhar, Nuh, Haryana, India. Research Journal of Pharmacy and Technology 2023; 16(1):179-3. doi: 10.52711/0974-360X.2023.00033 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-1-33
REFERENCES:
1. Rokade M. Khandagale P. Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10(3):241-244. DOI: 10.5958/2231-5691.2020.00025.8
2. Vishnu KN. Uppala PK. Vangoori Y. Gudhanti SN. A Review on Covid- 19 Pandemic and its Global Effects. Asian Journal of Pharmaceutical Research.2021; 4:11 DOI: 10.52711/2231-5691.2021.00042
3. Ministry of Health and family welfare Government of India. Dated- 28/10/2020 Morning [cited 2021 Febuary 18]. Available onlin athttps://www.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf
4. Habibunisha H. RathinamVA. Nivethitha K.A. Study on perception on Covid- 19 vaccination among general public. Asian Journal of Nursing Education and Research. 2021; 11(4): 537-0.DOI 10.52711/2349-2996.2021.00127.
5. Agarwal AK. Agarwal Al. Mahor R. Pathak A. A Cross Sectional Study to identify managerial issues in the Implementation of vaccination of under-five Children for effective management of Immunization Center. Asian Journal of Management. 2021; 12(3): 265-0. DOI: 10.52711/2321-5763.2021.00040
6. Center for Disease Control and Prevention. Food and Drug Administration. Vaccine adverse event reporting system. VAERS form, https://vaers.hhs. gov/resources/vaers_form.pdf (accessed January 2020.
7. Health Department Government of Haryana. Media Bulletin on COVID-19, Dated- 31/01/2021 Morning [cited 2021 Febuary 06]. Available online at http://nhmharyana.gov.in/WriteReadData/userfiles/file/CoronaVirus/Daily%20Bulletin%20of%20COVID%2019%20as%20on%2005-02-2021.pdf
8. Yadav P. Rohane S. Velhal A. Adverse Drug Reactions and Comorbidities in Patient Treated for COVID-19. Asian Journal of Research in Chemistry. 2021; 14(6):451-4.DOI: 10.52711/0974-4150.2021.00079
9. Mehta P et al. Identifying Backwardness of Mewat Region in Haryana: A Block-Level Analysis. New Delhi: Sehgal Foundation.(2015)
10. https://www.canada.ca/en/health-canada/services/drugs- health products/ covid19 industry/drugs vaccines-treatments/interim-order-import-sale-advertising drugs. html#a2.8.
11. Usha NS. Sushmitha HS. Kumar VG. A Study to assess side effects of first dose of Covid-19 Vaccination among GNM students studying at JSS School of Nursing Chamarajanagar. Asian Journal of Nursing Education and Research. 2021; 11(4):552-4.
12. Yadav R. Vaccines Other Than Specified in National Immunization Schedule among Parents of under- five Children. Int. J. Adv. Nur. Management2015; 3(1):64-68.
13. Aher VD. Banerjee S. Mahaur KK. Vaccine: An Ultimate Way of Immunization. Research J. Pharm. and Tech. March 2011; 4(3):369-374.
14. Balai MK. UK Variant COVID-19. Asian Journal of Nursing Education and Research. 2021; 11(4): 601-4. DOI: 10.52711/2349-2996.2021.00140
15. Kashyap S. BioN Tech CEO confident vaccine will work on new UK variant. One India News. 22 Dec. 2020. Accessed on 16 Jan.2021. Available at: https://www.oneindia.com/international/biontech-ceo-confident- vaccine-will-work-on-new-uk-variant-3192703.html
16. AEFI: surveillance and response. Operational guideline 2015. Ministry of health & family welfare Government of India, https://nhm.gov. in/New_Updates_2018/NHM_Components/Immunization/Guildelines_for_immunization/ AEFI_Surveillance_and_Response_Operational_ Guidelines_2015.pdf (accessed January 2020).
17. Singh AK. Wagner AL. Joshi J. Application of the revised WHO causality assessment protocol for adverse events following immunization in India. Vaccine 2017; 35: 4197–4202. DOI: 10.1016/j.vaccine.2017.06.027
18. Poland GA. Ovsyannikova IG. Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J 2009; 28: 431–433. DOI: 10.1586/14760584.2015.1038249
19. Kaur U et al. prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India E Clinical Medicine 2021;38:101038. DOI: 10.1016/j.eclinm.2021.101038
20. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single blind, randomised controlled trial. Lancet 2020; 396: 467–78. DOI: 10.1016/S0140-6736(20)31604-4
21. Ramasamy MN. Minassian AM. Ewer KJ. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020; 396: 1979–93. DOI: 10.1016/S0140-6736(20)32466-1
22. Joshi ND. Prajapati HK. Solanki KC. Pattern of adverse events following immunization in an Indian teaching hospital. Int J Med Sci Public Health 2013; 2: 62–68. DOI: 10.5455/IJMSPH. 2013.2 62-68.A
23. Aherkar RY, Deshpande and Ghongane BB. Study of the pattern of adverse events following immunization of children in a tertiary care hospital. PK Int J Basic Clin Pharmacol 2016;5:609–615. DOI:10.18203/2319-2003.ijbcp20161423
24. Zhu F-C. Guan X-H. Li Y-H. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396: 479–88. DOI: 10.1016/S0140-6736(20)31605-6
25. Rubingh J. van der Spek A. Fliers E. Boelen A. The role of thyroid hormone in the innate and adaptive immune response during infection. Compr Physiol2020; 10: 1277–87. DOI:10.1002/cphy.c200003
26. Brix TH. Hegedus L. Hallas J. Lund LC. Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism. Lancet Diabetes Endocrinol 2021; 9: 197–9.
DOI: 10.3389/fendo.2021.779692